Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases

This interventional study evaluated the efficacy of Naderin (sodium nucleinate) for the prophylaxis of complications during basic therapy and medical rehabilitation in patients with socially significant diseases, including malignant neoplasms, tuberculosis, and hepatitis C. The study assessed the immunocorrective effects of Naderin on hematological parameters, the incidence of infectious complications, and clinical outcomes. A total of 75 patients (40 in the main group and 35 in the control group) were enrolled. Patients in the main group received Naderin as an adjunct to standard therapy, while the control group received standard therapy without immunocorrection. The study demonstrated that Naderin reduced the duration of neutropenia by 4-5 days, attenuated the decline in white blood cell and lymphocyte counts during chemotherapy, and reduced the incidence of treatment interruptions due to complications. These findings suggest that Naderin may serve as an effective immunomodulatory agent for supportive care in patients with socially significant diseases.

NCT Number	NCT07671508
Lead Sponsor	MIPO Clinic
Conditions	Malignant Neoplasms, Tuberculosis (TB), HEPATITIS C (HCV)
Enrollment	75 participants
Start Date	2013-05-15
Primary Completion	2013-09-21 (estimated)
Study Completion	2014-03-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-30